3SBio Valuation Multiples

3SBio Overview

About 3SBio

3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics.

Founded

2006

HQ

Employees

5.6K

Website

3sbio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2B

EBITDA: $1B

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

3SBio Financials

3SBio reported last 12-month revenue of $2B and EBITDA of $1B.

In the same LTM period, 3SBio generated $2B in gross profit, $1B in EBITDA, and $983M in net income.

3SBio P&L

In the most recent fiscal year, 3SBio reported revenue of $1B and EBITDA of $484M.

3SBio expects next 12-month revenue of XXX and NTM EBITDA of XXX

3SBio Stock Performance

3SBio has current market cap of $8B, and enterprise value of $7B.

3SBio's stock price is $3.23.

3SBio Valuation Multiples

3SBio trades at 3.1x EV/Revenue multiple, and 5.4x EV/EBITDA.

3SBio Financial Valuation Multiples

As of April 19, 2026, 3SBio has market cap of $8B and EV of $7B.

Equity research analysts estimate 3SBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

3SBio has a P/E ratio of 7.7x.

3SBio Margins & Growth Rates

3SBio's revenue in the last 12 month declined by (31%).

3SBio's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

3SBio's rule of 40 is (1%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

3SBio's rule of X is (62%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

3SBio Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

3SBio M&A Activity

3SBio acquired XXX companies to date.

Last acquisition by 3SBio was on XXXXXXXX, XXXXX. 3SBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

3SBio Investment Activity

3SBio invested in XXX companies to date.

3SBio made its latest investment on XXXXXXXX, XXXXX. 3SBio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).